ROS1 rearrangements are reported in approximately 2% of NSCLC cases, resulting in the constitutive activation of a chimeric fusion protein and the dysregulation of a tyrosine kinase-mediated signaling pathway [95]. Here, ROS1 is linked to non-small cell lung carcinoma.